Approval · Notice of Compliance 23983 · 2020
OZEMPIC: Notice of Compliance 23983
Issued July 31, 2020
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 23983
- Date
- July 31, 2020
- Company
- Novo Nordisk Canada IncMississauga, Ontario, Canada
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Expansion of indication: Ozempic to be used in combination with: metformin or a sulfonylurea and a sodium-glucose cotransporter 2 inhibitor (SGLT2i) when diet and exercise plus metformin or a sulfonylurea, in addition to an SGLT2i, do not achieve adequate glycemic control.
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| OZEMPIC | Not yet assigned | — |
Medicinal ingredients
- SEMAGLUTIDE 1.34 MG per ML